Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China
•Antivirus activities, adverse reactions, advance on COVID-19 treatment, and general usage of potential chemical drugs against SARS-CoV-2 are summarized.•Various TCMs with practical effects, including Chinese herbal compound prescriptions, injection preparations, and active ingredients of TCMs, on t...
Gespeichert in:
| Veröffentlicht in: | Virus research 2020-09, Vol.286, p.198057-198057, Article 198057 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 198057 |
|---|---|
| container_issue | |
| container_start_page | 198057 |
| container_title | Virus research |
| container_volume | 286 |
| creator | Pan, Xiaoqi Dong, Lan Yang, Lian Chen, Dayi Peng, Cheng |
| description | •Antivirus activities, adverse reactions, advance on COVID-19 treatment, and general usage of potential chemical drugs against SARS-CoV-2 are summarized.•Various TCMs with practical effects, including Chinese herbal compound prescriptions, injection preparations, and active ingredients of TCMs, on the treatment of COVID-19 are reviewed.•Biological products, such as interferon-α, vaccines, stem cells, and convalescent plasma, are concluded to treat COVID-19.
The fight against the novel coronavirus pneumonia (namely COVID-19) that seriously harms human health is a common task for all mankind. Currently, development of drugs against the novel coronavirus (namely SARS-CoV-2) is quite urgent. Chinese medical workers and scientific researchers have found some drugs to play potential therapeutic effects on COVID-19 at the cellular level or in preliminary clinical trials. However, more fundamental studies and large sample clinical trials need to be done to ensure the efficacy and safety of these drugs. The adoption of these drugs without further testing must be careful. The relevant articles, news, and government reports published on the official and Preprint websites, PubMed and China National Knowledge Infrastructure (CNKI) databases from December 2019 to April 2020 were searched and manually filtered. The general pharmacological characteristics, indications, adverse reactions, general usage, and especially current status of the treatment of COVID-19 of those potentially effective drugs, including chemical drugs, traditional Chinese medicines (TCMs), and biological products in China were summarized in this review to guide reasonable medication and the development of specific drugs for the treatment of COVID-19. |
| doi_str_mv | 10.1016/j.virusres.2020.198057 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7282797</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168170220302501</els_id><sourcerecordid>32531236</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3867-416ec4121f40782c28213e78f5e88e492c0eff886b9cd901feea092a57be54f43</originalsourceid><addsrcrecordid>eNqFkMtOAjEUhhujEby8AulSF4Nt59LOxmjGGwkJLtS4a0rnFEqgJZ2BxLe3gBBduWpyzn_p-RDqUdKnhBY3s_7ahlUToOkzwuKwFCTnR6hLBWcJz0p2jLpRKBLKCeugs6aZEUKKlBenqJOyPKUsLbro89W34Fqr5rgOq0mDjQ-4nQJuA6h2EVfYm-3A-TXMsfbBO7XtxksHq4V3VuGravQxeEhoeY2tw9XUOnWBToyaN3D5856j96fHt-olGY6eB9X9MNGpKHiS0QJ0Rhk1GeGCaSYYTYELk4MQEM_QBIwRohiXui4JNQCKlEzlfAx5ZrL0HN3ucper8QJqHX8c1Fwug12o8CW9svLvxtmpnPi15LGKlzwGFLsAHXwTgZqDlxK5YS1ncs9abljLHeto7P1uPtj2cKPgbieAeP_aQpCNtuA01DaAbmXt7X8d35mjlOo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Pan, Xiaoqi ; Dong, Lan ; Yang, Lian ; Chen, Dayi ; Peng, Cheng</creator><creatorcontrib>Pan, Xiaoqi ; Dong, Lan ; Yang, Lian ; Chen, Dayi ; Peng, Cheng</creatorcontrib><description>•Antivirus activities, adverse reactions, advance on COVID-19 treatment, and general usage of potential chemical drugs against SARS-CoV-2 are summarized.•Various TCMs with practical effects, including Chinese herbal compound prescriptions, injection preparations, and active ingredients of TCMs, on the treatment of COVID-19 are reviewed.•Biological products, such as interferon-α, vaccines, stem cells, and convalescent plasma, are concluded to treat COVID-19.
The fight against the novel coronavirus pneumonia (namely COVID-19) that seriously harms human health is a common task for all mankind. Currently, development of drugs against the novel coronavirus (namely SARS-CoV-2) is quite urgent. Chinese medical workers and scientific researchers have found some drugs to play potential therapeutic effects on COVID-19 at the cellular level or in preliminary clinical trials. However, more fundamental studies and large sample clinical trials need to be done to ensure the efficacy and safety of these drugs. The adoption of these drugs without further testing must be careful. The relevant articles, news, and government reports published on the official and Preprint websites, PubMed and China National Knowledge Infrastructure (CNKI) databases from December 2019 to April 2020 were searched and manually filtered. The general pharmacological characteristics, indications, adverse reactions, general usage, and especially current status of the treatment of COVID-19 of those potentially effective drugs, including chemical drugs, traditional Chinese medicines (TCMs), and biological products in China were summarized in this review to guide reasonable medication and the development of specific drugs for the treatment of COVID-19.</description><identifier>ISSN: 0168-1702</identifier><identifier>EISSN: 1872-7492</identifier><identifier>DOI: 10.1016/j.virusres.2020.198057</identifier><identifier>PMID: 32531236</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adenosine Monophosphate - analogs & derivatives ; Adenosine Monophosphate - therapeutic use ; Alanine - analogs & derivatives ; Alanine - therapeutic use ; Amides - therapeutic use ; Antiviral Agents - therapeutic use ; Betacoronavirus - drug effects ; Betacoronavirus - immunology ; Biological products ; Chemical drugs ; China - epidemiology ; Chloroquine - therapeutic use ; Coronavirus Infections - drug therapy ; Coronavirus Infections - epidemiology ; Coronavirus Infections - mortality ; Coronavirus Infections - virology ; COVID-19 ; Drug Combinations ; Drugs, Chinese Herbal - therapeutic use ; Humans ; Indoles - therapeutic use ; Interferons - therapeutic use ; Lopinavir - therapeutic use ; Lung - drug effects ; Lung - pathology ; Lung - virology ; Pandemics ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - mortality ; Pneumonia, Viral - virology ; Pyrazines - therapeutic use ; Ribavirin - therapeutic use ; Ritonavir - therapeutic use ; SARS-CoV-2 ; Survival Analysis ; Traditional Chinese medicines</subject><ispartof>Virus research, 2020-09, Vol.286, p.198057-198057, Article 198057</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><rights>2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3867-416ec4121f40782c28213e78f5e88e492c0eff886b9cd901feea092a57be54f43</citedby><cites>FETCH-LOGICAL-c3867-416ec4121f40782c28213e78f5e88e492c0eff886b9cd901feea092a57be54f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168170220302501$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32531236$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pan, Xiaoqi</creatorcontrib><creatorcontrib>Dong, Lan</creatorcontrib><creatorcontrib>Yang, Lian</creatorcontrib><creatorcontrib>Chen, Dayi</creatorcontrib><creatorcontrib>Peng, Cheng</creatorcontrib><title>Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China</title><title>Virus research</title><addtitle>Virus Res</addtitle><description>•Antivirus activities, adverse reactions, advance on COVID-19 treatment, and general usage of potential chemical drugs against SARS-CoV-2 are summarized.•Various TCMs with practical effects, including Chinese herbal compound prescriptions, injection preparations, and active ingredients of TCMs, on the treatment of COVID-19 are reviewed.•Biological products, such as interferon-α, vaccines, stem cells, and convalescent plasma, are concluded to treat COVID-19.
The fight against the novel coronavirus pneumonia (namely COVID-19) that seriously harms human health is a common task for all mankind. Currently, development of drugs against the novel coronavirus (namely SARS-CoV-2) is quite urgent. Chinese medical workers and scientific researchers have found some drugs to play potential therapeutic effects on COVID-19 at the cellular level or in preliminary clinical trials. However, more fundamental studies and large sample clinical trials need to be done to ensure the efficacy and safety of these drugs. The adoption of these drugs without further testing must be careful. The relevant articles, news, and government reports published on the official and Preprint websites, PubMed and China National Knowledge Infrastructure (CNKI) databases from December 2019 to April 2020 were searched and manually filtered. The general pharmacological characteristics, indications, adverse reactions, general usage, and especially current status of the treatment of COVID-19 of those potentially effective drugs, including chemical drugs, traditional Chinese medicines (TCMs), and biological products in China were summarized in this review to guide reasonable medication and the development of specific drugs for the treatment of COVID-19.</description><subject>Adenosine Monophosphate - analogs & derivatives</subject><subject>Adenosine Monophosphate - therapeutic use</subject><subject>Alanine - analogs & derivatives</subject><subject>Alanine - therapeutic use</subject><subject>Amides - therapeutic use</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Betacoronavirus - drug effects</subject><subject>Betacoronavirus - immunology</subject><subject>Biological products</subject><subject>Chemical drugs</subject><subject>China - epidemiology</subject><subject>Chloroquine - therapeutic use</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronavirus Infections - mortality</subject><subject>Coronavirus Infections - virology</subject><subject>COVID-19</subject><subject>Drug Combinations</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Humans</subject><subject>Indoles - therapeutic use</subject><subject>Interferons - therapeutic use</subject><subject>Lopinavir - therapeutic use</subject><subject>Lung - drug effects</subject><subject>Lung - pathology</subject><subject>Lung - virology</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Pneumonia, Viral - mortality</subject><subject>Pneumonia, Viral - virology</subject><subject>Pyrazines - therapeutic use</subject><subject>Ribavirin - therapeutic use</subject><subject>Ritonavir - therapeutic use</subject><subject>SARS-CoV-2</subject><subject>Survival Analysis</subject><subject>Traditional Chinese medicines</subject><issn>0168-1702</issn><issn>1872-7492</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOAjEUhhujEby8AulSF4Nt59LOxmjGGwkJLtS4a0rnFEqgJZ2BxLe3gBBduWpyzn_p-RDqUdKnhBY3s_7ahlUToOkzwuKwFCTnR6hLBWcJz0p2jLpRKBLKCeugs6aZEUKKlBenqJOyPKUsLbro89W34Fqr5rgOq0mDjQ-4nQJuA6h2EVfYm-3A-TXMsfbBO7XtxksHq4V3VuGravQxeEhoeY2tw9XUOnWBToyaN3D5856j96fHt-olGY6eB9X9MNGpKHiS0QJ0Rhk1GeGCaSYYTYELk4MQEM_QBIwRohiXui4JNQCKlEzlfAx5ZrL0HN3ucper8QJqHX8c1Fwug12o8CW9svLvxtmpnPi15LGKlzwGFLsAHXwTgZqDlxK5YS1ncs9abljLHeto7P1uPtj2cKPgbieAeP_aQpCNtuA01DaAbmXt7X8d35mjlOo</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Pan, Xiaoqi</creator><creator>Dong, Lan</creator><creator>Yang, Lian</creator><creator>Chen, Dayi</creator><creator>Peng, Cheng</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20200901</creationdate><title>Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China</title><author>Pan, Xiaoqi ; Dong, Lan ; Yang, Lian ; Chen, Dayi ; Peng, Cheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3867-416ec4121f40782c28213e78f5e88e492c0eff886b9cd901feea092a57be54f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adenosine Monophosphate - analogs & derivatives</topic><topic>Adenosine Monophosphate - therapeutic use</topic><topic>Alanine - analogs & derivatives</topic><topic>Alanine - therapeutic use</topic><topic>Amides - therapeutic use</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Betacoronavirus - drug effects</topic><topic>Betacoronavirus - immunology</topic><topic>Biological products</topic><topic>Chemical drugs</topic><topic>China - epidemiology</topic><topic>Chloroquine - therapeutic use</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronavirus Infections - mortality</topic><topic>Coronavirus Infections - virology</topic><topic>COVID-19</topic><topic>Drug Combinations</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Humans</topic><topic>Indoles - therapeutic use</topic><topic>Interferons - therapeutic use</topic><topic>Lopinavir - therapeutic use</topic><topic>Lung - drug effects</topic><topic>Lung - pathology</topic><topic>Lung - virology</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Pneumonia, Viral - mortality</topic><topic>Pneumonia, Viral - virology</topic><topic>Pyrazines - therapeutic use</topic><topic>Ribavirin - therapeutic use</topic><topic>Ritonavir - therapeutic use</topic><topic>SARS-CoV-2</topic><topic>Survival Analysis</topic><topic>Traditional Chinese medicines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Xiaoqi</creatorcontrib><creatorcontrib>Dong, Lan</creatorcontrib><creatorcontrib>Yang, Lian</creatorcontrib><creatorcontrib>Chen, Dayi</creatorcontrib><creatorcontrib>Peng, Cheng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Virus research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Xiaoqi</au><au>Dong, Lan</au><au>Yang, Lian</au><au>Chen, Dayi</au><au>Peng, Cheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China</atitle><jtitle>Virus research</jtitle><addtitle>Virus Res</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>286</volume><spage>198057</spage><epage>198057</epage><pages>198057-198057</pages><artnum>198057</artnum><issn>0168-1702</issn><eissn>1872-7492</eissn><abstract>•Antivirus activities, adverse reactions, advance on COVID-19 treatment, and general usage of potential chemical drugs against SARS-CoV-2 are summarized.•Various TCMs with practical effects, including Chinese herbal compound prescriptions, injection preparations, and active ingredients of TCMs, on the treatment of COVID-19 are reviewed.•Biological products, such as interferon-α, vaccines, stem cells, and convalescent plasma, are concluded to treat COVID-19.
The fight against the novel coronavirus pneumonia (namely COVID-19) that seriously harms human health is a common task for all mankind. Currently, development of drugs against the novel coronavirus (namely SARS-CoV-2) is quite urgent. Chinese medical workers and scientific researchers have found some drugs to play potential therapeutic effects on COVID-19 at the cellular level or in preliminary clinical trials. However, more fundamental studies and large sample clinical trials need to be done to ensure the efficacy and safety of these drugs. The adoption of these drugs without further testing must be careful. The relevant articles, news, and government reports published on the official and Preprint websites, PubMed and China National Knowledge Infrastructure (CNKI) databases from December 2019 to April 2020 were searched and manually filtered. The general pharmacological characteristics, indications, adverse reactions, general usage, and especially current status of the treatment of COVID-19 of those potentially effective drugs, including chemical drugs, traditional Chinese medicines (TCMs), and biological products in China were summarized in this review to guide reasonable medication and the development of specific drugs for the treatment of COVID-19.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32531236</pmid><doi>10.1016/j.virusres.2020.198057</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-1702 |
| ispartof | Virus research, 2020-09, Vol.286, p.198057-198057, Article 198057 |
| issn | 0168-1702 1872-7492 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7282797 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adenosine Monophosphate - analogs & derivatives Adenosine Monophosphate - therapeutic use Alanine - analogs & derivatives Alanine - therapeutic use Amides - therapeutic use Antiviral Agents - therapeutic use Betacoronavirus - drug effects Betacoronavirus - immunology Biological products Chemical drugs China - epidemiology Chloroquine - therapeutic use Coronavirus Infections - drug therapy Coronavirus Infections - epidemiology Coronavirus Infections - mortality Coronavirus Infections - virology COVID-19 Drug Combinations Drugs, Chinese Herbal - therapeutic use Humans Indoles - therapeutic use Interferons - therapeutic use Lopinavir - therapeutic use Lung - drug effects Lung - pathology Lung - virology Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - epidemiology Pneumonia, Viral - mortality Pneumonia, Viral - virology Pyrazines - therapeutic use Ribavirin - therapeutic use Ritonavir - therapeutic use SARS-CoV-2 Survival Analysis Traditional Chinese medicines |
| title | Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T22%3A45%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20drugs%20for%20the%20treatment%20of%20the%20novel%20coronavirus%20pneumonia%20(COVID-19)%20in%20China&rft.jtitle=Virus%20research&rft.au=Pan,%20Xiaoqi&rft.date=2020-09-01&rft.volume=286&rft.spage=198057&rft.epage=198057&rft.pages=198057-198057&rft.artnum=198057&rft.issn=0168-1702&rft.eissn=1872-7492&rft_id=info:doi/10.1016/j.virusres.2020.198057&rft_dat=%3Cpubmed_cross%3E32531236%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32531236&rft_els_id=S0168170220302501&rfr_iscdi=true |